Descrizione del progetto DEENESFRITPL Un nuovo farmaco contro l’artrite reumatoide L’artrite reumatoide è una condizione autoimmune associata a dolore e rigidità delle articolazioni provocati dall’infiammazione. L’obiettivo del progetto RheumArth, finanziato dall’UE, è introdurre il nuovo farmaco AP1189 per la convalida clinica. AP1189 è un agonista contro i recettori della melanocortina che oltre a regolare la pigmentazione cutanea sembra anche inibire l’infiammazione. L’idea è di utilizzare AP1189 per favorire la risoluzione dell’infiammazione legata all’artrite reumatoide. I promettenti dati clinici preliminari relativi alla sicurezza hanno gettato le basi per la convalida dell’efficacia clinica del farmaco AP1189 nei pazienti affetti da questa condizione. Mostra l’obiettivo del progetto Nascondi l’obiettivo del progetto Obiettivo Rheumatoid arthritis (RA) is a chronic autoimmune disorder causing inflammation and permanent damage in joints and surrounding tissues - leading to severe disability, decreased quality of life, and reduced life expectancy. The disease affects more than 6 million people with annual costs amounting to €45billion in the Europe (EU) alone. There is a wide range of drug therapies for RA, mobilizing a variety of anti-inflammatory and immune modulating effects. However, a significant proportion (30%) of the patients do not respond to current treatments, efficacy is often reduced over time and the incidence of side effects is high and can be severe and life threatening.AP1189 is new chemically-synthesized small molecule drug for the treatment of Rheumatoid arthritis (RA). Through specific activation of the patients’ self-anti-inflammatory mechanisms, our first drug candidate renders unprecedent combination of safety, effectiveness and patient compliance, without the side effects associated with current therapies. The clinical validation of our drug for RA - 1st indication (foreseen for the Innovation Project) - will not only open a large market within this therapeutic area, as it will allow Synact to set a market foothold in the chronic inflammatory disease market, supporting the company´s medium term strategic positioning as an unique provider of a new generation of anti-inflammatory drugs. AP1189 clinical validation is on-going with current Phase I clinical trials showing promising preliminary results – safety and tolerance was proved in healthy human volunteers. Next step in the development will be a Phase IIa Proof-Of-Concept (POC) trail to validate our drug´s efficacy profile in RA patients. In this context, the present Phase 1 will be of utmost importance to validate AP1189´s market position and potential in RA and prepare the large clinical validation aimed for in the ensuing SME Instrument Phase II project. Campo scientifico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicinerheumatologymedical and health scienceshealth sciencesinflammatory diseases Programma(i) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Argomento(i) EIC-SMEInst-2018-2020 - SME instrument Invito a presentare proposte H2020-EIC-SMEInst-2018-2020 Vedi altri progetti per questo bando Bando secondario H2020-SMEInst-2018-2020-1 Meccanismo di finanziamento SME-1 - SME instrument phase 1 Coordinatore SYNACT PHARMA APS Contribution nette de l'UE € 50 000,00 Indirizzo DRONNINGGARDS ALLE 136 2840 HOLTE Danimarca Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Danmark Hovedstaden Nordsjælland Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 71 429,00